GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Gilead Sciences

Johnson & Johnson

Moderna

Novavax

Sanofi

As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.

These 6  Drug Companies are Testing a Coronavirus Vaccine

The clinical-stage biotech from China has a promising coronavirus vaccine candidate. If it works, the big British pharma has a compound that could help it work better.

GlaxoSmithKline Signs COVID-19 Collaboration Deal With Clover Biopharmaceuticals

Shares of GlaxoSmithKline Plc GSK, -1.39% fell 1.8% in premarket trading on Monday after the drugmaker said it plans to test its technology with Chinese biotech Clover Biopharmaceuticals's vaccine candidate for COVID-19.

GSK's stock falls after it announces new coronavirus vaccine partnership

Private equity-backed generic drugmaker Stada  said it has agreed to buy 15 consumer healthcare products from British drugmaker GlaxoSmithKline  to further strengthen its prescription-free drugs business in Europe.

Exclusive: Germany's Stada buys 15 GSK consumer health brands

A clinical trial suggests the COPD drug reduces the risk of death compared to GSK's older treatment, but the agency has concerns about the study's design.

FDA's Advisory Committee to Review Claims That GlaxoSmithKline's Trelegy Ellipta Reduces Mortality

The global pharmaceutical giant will team up with a German biotech to research and develop T-cell based therapies.

GlaxoSmithKline Signs Potential $600 Million-Plus Cancer Immunotherapy Research-Partnership Deal

Bristol-Myers

Mylan

Novartis

Pfizer

Teva Pharmaceutical

Approvals were down slightly year over year.

FDA Approved 1,014 Generic Drugs in 2019

Shares of Glaxo (GSK) lag the industry in a year as generic erosion of some drugs mainly its top-selling drug, Advair offsets strong sales of new drugs.

Glaxo Underperforms Industry in a Year: What's in Store?

Alcon Inc. - Registered Shares

The switch will increase the availability of pain and allergy drugs from GlaxoSmithKline and Alcon.

FDA Approves 3 Drugs for the Switch From Prescription to Over the Counter

Philip Morris

AT&T

3 Top Dividend Stocks With Yields Over  5%

Which of these top pharma stocks is the better buy right now?

Better Buy: GlaxoSmithKline vs.  Bristol-Myers Squibb

The U.K.-based pharmaceutical company is in a transition period.

Where Will GlaxoSmithKline Be in 5 Years?

The workforce reduction is one of the moves being made to prepare for the pharmaceutical company's upcoming split into two entities.

GlaxoSmithKline Cutting Up to 720 Jobs at European Vaccine Facility

Glaxo (GSK) misses on earnings and sales in the fourth quarter. The company expects earnings to decline in 2020.

Glaxo (GSK) Lags Q4 Earnings & Revenue Estimates, Stock Down

GlaxoSmithKline plc (GSK) CEO Emma Walmsley on Q4 2019 Results - Earnings Call Transcript

The pharmaceutical giant's fourth-quarter 2019 earnings were disappointing, but there were things for investors to smile about in the new details on its upcoming spinoff.

GlaxoSmithKline Predicts a 2020 Loss, Prepares for Its Consumer Spinoff

GlaxoSmithKline plans to spin off its consumer health care business, leading GSK stock to slip in early action. The new GSK focuses on the immune system, genetics and new technologies, 
The post GSK Stock Trips On Earnings Lag, Plan To Spin Out Consumer Health appeared first on Investor's Business Daily.

GSK Stock Trips On Earnings Lag, Plan To Spin Out Consumer Health

Glaxo misses both earnings and sales estimates in the fourth quarter of 2019. The company initiates separation program to split itself into two standalone units.

Glaxo (GSK) Misses Earnings & Revenue Estimates in Q4

GlaxoSmithKline on Wednesday reported quarterly profit that fell short of analysts' expectations because of pricing pressure, mainly hitting its respiratory drugs.

GlaxoSmithKline's profit hit by pricing pressure, sees lower 2020 profit

U.K. pharmaceutical giant GlaxoSmithKline GSK, +0.83% GSK, +0.78% said fourth-quarter adjusted earnings per share fell 21% to 24.8 pence, while revenue rose 9% to £8.9 billion, as it also said it's planning to split into two companies in two years.

Glaxo says adjusted EPS slips as it prepares to split into two companies

Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven sales in the fourth quarter.

Is a Disappointment in Store for Glaxo's (GSK) Q4 Earnings?

GlaxoSmithKline's Priority Review For Cancer Drug Sets It Up For First Of A Kind FDA Approval

Glaxo's (GSK) BLA for belantamab mafodotin gains the FDA priority review status to treat heavily pre-treated patients with relapsed or refractory multiple myeloma.

Glaxo's Multiple Myeloma Candidate Gets FDA's Priority Review

The Food and Drug Administration officially granted a priority review to the first of what could be many BCMA-targeted drugs.

FDA Puts GlaxoSmithKline's Blood Cancer Drug In the Fast Lane

Is GlaxoSmithKline (GSK) a great pick from the value investor's perspective right now? Read on to know more.

News for GlaxoSmithKline Stock (GSK)